RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs
Since Gleevec was approved in 2001, over 40 other tyrosine kinase inhibitors have come onto the market to treat various types of cancer. But with the proliferation of the class also came a surge of acquired resistance, where patients’ tumors mutate around the drug target and stop responding to the therapies.
Tyra Bio, a Carlsbad, CA-based biotech “purpose built” to address that problem, has just raised $50 million from Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group, and Canaan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.